Although problems in US healthcare abound, the most insidious challenges are often tightly coupled with the industry’s most appealing and instilled virtues a highly selective and independent workforce, (b) an extremely low tolerance for risk, and (c) a high degree of professional oversight.
M Mark Mofid, Author at MedCity News medcitynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medcitynews.com Daily Mail and Mail on Sunday newspapers.
Shifting the healthcare system to an upstream approach will take a lot of work, but young people desperately need it, and the healthcare system direly needs it as well.
Frank Forte, Author at MedCity News medcitynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medcitynews.com Daily Mail and Mail on Sunday newspapers.
The first gene therapies for sickle cell disease are now approved: Casgevy from Vertex Pharmaceuticals Casgevy and Lyfgenia from Bluebird Bio. Despite the same-day approval, key differences give one of these therapies commercialization advantages over the other.